What Is The Role Of Genomic Testing In Glioblastoma?

Genomic testing plays an increasingly important role in understanding glioblastoma. Rather than looking only at how tumour cells appear under a microscope, specialists can examine a much more specific range of factors.

These include how the cells genetic and molecular characteristics help confirm the diagnosis, understand how the tumour is likely to behave and inform treatment decisions.

This approach is part of a broader move towards more precise, personalised care in neuro-oncology. For someone diagnosed with glioblastoma, genomic testing can therefore provide information that complements MRI scans, pathology and clinical assessment.

What is genomic testing?

Genomic testing examines DNA and other molecular features within tumour cells. This can involve looking for specific gene mutations, changes in chromosomes, alterations in DNA repair mechanisms or patterns of DNA methylation.

A tissue sample obtained during a biopsy or surgery is commonly used. The results are considered alongside the appearance of the tumour under the microscope and the patient's clinical and imaging findings.

This is important because glioblastomas are not all molecularly identical. Genetic and epigenetic differences can affect how a tumour is classified and how it responds to treatment.

How does genomic testing help diagnose glioblastoma?

Modern brain tumour diagnosis increasingly combines histology with molecular information. One of the most important markers is IDH status.

IDH1 and IDH2 alterations are found in a small proportion of tumours classified as glioblastoma, while most glioblastomas are IDH-wildtype. Establishing IDH status can therefore help specialists determine the precise tumour classification.

Other molecular findings can also contribute to diagnosis. For example, changes involving genes such as EGFR and TERT, as well as specific chromosome copy-number changes, can be relevant in certain cases.

This illustrates why genomic information is not simply an additional piece of data. In some cases, it can change how a tumour is classified.

What does MGMT testing tell specialists?

One of the most clinically relevant molecular tests in glioblastoma examines MGMT promoter methylation. MGMT is involved in repairing damaged DNA. When the MGMT promoter is methylated, production of the MGMT repair enzyme can be reduced.

This may make tumour cells more susceptible to alkylating chemotherapy such as temozolomide. MGMT promoter methylation is also associated with prognosis in newly diagnosed glioblastoma.

Can genomic testing identify potential treatment targets?

Another important role of genomic testing is identifying molecular alterations that could potentially be relevant to treatment. Research has identified a wide range of genetic changes in glioblastoma, including alterations involving EGFR, PDGFRA, NF1 and IDH1.

Large-scale genomic studies have helped researchers understand the biological diversity of glioblastoma and identify potential targets for future therapies.

In clinical practice, however, finding a genetic alteration does not automatically mean that there is an established treatment specifically designed to target it.

Some molecular findings may be most useful for diagnosis or research, while others may help determine eligibility for a clinical trial.

Does genomic testing affect treatment planning?

The results can contribute to decisions about treatment, alongside factors such as tumour location, extent of surgery, MRI findings, overall health and previous treatment.

For example, MGMT promoter methylation can provide useful information when specialists are considering chemotherapy. Other molecular findings may influence tumour classification or help determine whether a patient could be considered for a particular clinical trial.

Genomic information can also become relevant if a tumour changes over time. At recurrence, additional testing may be considered because the molecular characteristics of a tumour can provide further information about its biology and potential treatment options.

What does this mean for patients?

Genomic testing means that a glioblastoma diagnosis can be examined at a much deeper level than its appearance on an MRI scan or under a microscope.

The results may help answer several important questions:

• What type of tumour is this?
• What molecular characteristics does it have?
• What can those characteristics tell us about its behaviour?
• Could they influence treatment or clinical trial options?

Not every patient will require exactly the same panel of tests, and results need to be interpreted by specialists with experience in brain tumour diagnosis and treatment.

For patients and families, the key point is that genomic testing forms part of a wider diagnostic process.

By combining molecular findings with pathology, imaging and clinical assessment, specialist teams can build a more detailed understanding of the individual tumour and use that information to support personalised treatment planning.

Explore the Queen Square website to learn more about specialist glioblastoma diagnosis, genomic testing and personalised neurological care.